VEGFA and breast carcinoma: Overall, these data suggested that anti-VEGF therapy may delay or prevent the onset of endocrine therapy resistance in patients with hormone-sensitive breast cancer, supporting the use of the combined therapy with anti-angiogenic plus anti-hormonal agents in breast cancer.